Background {#Sec1}
==========

Endogenous endophthalmitis (EE) occurs when infectious agents are hematogenously disseminated into the eye from a remote focus of infection. Even though this entity is relatively rare and accounts for approximately 2--15% of all cases of endophthalmitis \[[@CR1]--[@CR3]\], it is an ocular emergency and is potentially life-threatening. The causative organisms may vary depending on the geographical location. In Europe and the USA, *Streptococcus species*, *Staphylococcus aureus*, and other gram-positive bacteria account for two thirds of bacterial endogenous endophthalmitis cases and gram-negative isolates are found in only 32% of cases \[[@CR3], [@CR4]\]. In contrast, most cases of EE in East Asia are caused by gram-negative organisms especially *Klebsiella species* accounting for 80 to 90% of positive cultures \[[@CR4], [@CR5]\].

The outcome of endogenous endophthalmitis is often dismal. Sharma et al. reported that 60% of the eyes had a final visual acuity of hand motions or worse and as many as 29% required removals \[[@CR6]\]. Hence, prompt diagnosis and management are essential if useful vision is to be preserved.

To the best of our knowledge, there is no large case series on endogenous endophthalmitis being reported yet from Malaysia. The current study was performed to determine the clinical profile of EE at a tertiary hospital while focusing on the clinical presentation, predisposing risk factors, source of infective microorganism, treatment outcomes and prognostic indicators.

Methods {#Sec2}
=======

A retrospective observational study was conducted in Selayang Hospital which was the main national tertiary referral center for uveitis in Malaysia. We reviewed the medical records of patients with endogenous endophthalmitis who were seen or referred to our hospital over a period of 9 years between January 2007 and December 2015. The diagnosis of endogenous endophthalmitis was defined as the presence of iritis and vitritis on ophthalmic examination and one or more of the following: (1) constitutional symptoms and systemic infection; (2) positive cultures of vitreous, blood, or other body fluids; (3) presence of loculation, vitreous debris, or membranous debris on ultrasound; (4) lack of ocular trauma or ocular surgery within 1 year from onset of infection or evidence of primary external ocular infection such as infectious keratitis or filtering bleb infection.

Demographic details such as age, gender and race, presenting complaints, preexisting medical illnesses, predisposing risk factors, source of infection, laterality, visual acuity, ophthalmologic examination, ultrasound findings, microbiologic profiles, treatment modalities, and final visual outcomes were collected from medical records.

The study was done according to Malaysian Good Clinical Practice (MGCP) 2nd edition January 2004 and registered in National Medical Research Register (NMRR).

Data was analyzed using the Statistical Package for Social Science (SPSS) version 22.0. Descriptive data was expressed as mean ± standard deviation (SD) for numerical data, and categorical variables were presented in frequencies and percentages. Logistic regression analysis was used to determine the factors associated with good visual outcomes. The association between presenting and final visual acuity was also analyzed using the Pearson correlation coefficient, and visual acuities were converted to logarithm of the minimal angle of resolution (logMAR) scale. For visual acuity less than counting finger (CF), the following scales were used: CF = 2.00 LogMAR units, hand motion = 2.30 LogMAR units, light perception = 2.60 LogMAR units, and no light perception = 2.90 LogMAR units. A *P* value of \< 0.05 was considered to be significant.

Results {#Sec3}
=======

Demographic data {#Sec4}
----------------

A total of 143 eyes of 120 patients were included in this study. The age of patients ranged from 7 to 81 years, and the mean age at presentation was 52.6 ± 15.1 years. The racial distribution reflected the multiracial population in our country with 72 Malays (60.0%), 33 Chinese (27.5%), 13 Indian (10.8%), and 2 others (1.7%). There was a slight female predominance (61, 50.8%) compared to males (59, 49.2%).

Systemic features {#Sec5}
-----------------

### Systemic risk factors {#Sec6}

At least one underlying medical illness was identified in 95 patients (79.2%). Diabetes mellitus was the most common medical illness (72, 60.0%), followed by renal failure (20, 16.7%), and 15 patients (12.5%) had solid organ tumor or hematologic malignancy. Six patients (5.0%) had liver disease and 3 patients (2.5%) were pregnant. Five patients (4.2%) were on systemic corticosteroids for underlying autoimmune diseases, and 1 was on systemic immunosuppressants.

### Source of infection {#Sec7}

A primary source of infection was identified in 90 patients (75.0%). Urinary tract infection (21, 17.5%) was the most common source of bacteremia followed by pulmonary infection (19, 15.8%), skin or soft tissue infection (17, 14.2%), and hepatobiliary infection (12, 10.0%). However, the source of infection could not be identified in 30 patients (25.0%), despite extensive systemic work-up and investigations (Table [1](#Tab1){ref-type="table"}).Table 1Identifiable source of infectionSource of infectionNo. of patientsPercentInfected catheter119.2Urinary tract infection2117.5Hepatobiliary infection1210.0Lung infection1915.8Meningitis21.7Infective endocarditis10.8Gastrointestinal infection10.8Genital infection21.7Skin or soft tissue infection1714.2Septic arthritis10.8Diabetic foot ulcer32.5Nil3025.0

### Ocular features {#Sec8}

#### Ocular symptoms {#FPar1}

Majority of patients had unilateral disease, 97 (80.8%), and involvement of the left eye (78, 54.5%) was more common. Blurring of vision (106, 74.1%), eye redness (52, 36.4%), eye pain or discomfort (42, 29.4%), and floaters (16, 11.2%) were ocular symptoms at presentation. The blurring of vision (85, 68.5%) was the most common presenting complaint, followed by eye redness (20, 16.1%) and eye pain or discomfort (14, 11.3%).

The interval between the onset of ocular symptoms and the first presentation to an ophthalmologist was less than 1 week in 62 eyes (47.3%), 1 to 2 weeks in 40 eyes (30.5%), more than 2 weeks to 1 month in 10 eyes (14.5%), and more than 1 month in 10 eyes (7.6%). The interval was not available in 12 eyes which were from patients with no recorded ocular symptoms due to poor general medical condition or no documentation obtained from the medical records (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The interval between the onset of ocular symptom and first presentation and the duration between systemic and ocular symptom

Systemic symptoms were identified in 84 patients (70.0%). This data was not available in 36 patients (30.0%). The interval between the onset of systemic symptoms and the onset of ocular symptoms was identified in 101 eyes. The interval was less than 1 week in 26 eyes (25.7%), between 1 and 2 weeks in 25 eyes (24.8%), more than 2 weeks to 1 month in 12 eyes (11.9%), and more than 1 month in 38 eyes (37.6%) (Fig. [1](#Fig1){ref-type="fig"}).

#### Ocular findings {#FPar2}

At presentation, based on the Standardization of Uveitis Nomenclature (SUN), the proportion of the eyes with anterior chamber cells better than grade 3 and grade 3 or worse was similar with 67 eyes (49.6%) and 68 eyes (50.4%) respectively. Twenty-seven eyes (19.0%) had hypopyon, and 42 eyes (29.6%) had fibrin. The fundal view was present in 64 out of 143 eyes (44.8%). Among this, 32 eyes (50.0%) had choroiditis or choroidal abscess, 11 eyes (17.2%) had retinitis, 6 (9.4%) had vasculitis, and 4 (6.3%) had optic disc swelling. Six eyes had a combination of choroiditis or choroidal abscess and retinitis and 2 eyes had choroiditis or choroidal abscess, vasculitis, and optic disc swelling.

Ultrasound findings were documented in 97 eyes. Fifty-five eyes (56.7%) had vitreous loculation, whereas subretinal or vitreous abscess and retinal detachment were found in 6 (6.2%) and 8 (8.2%) eyes respectively.

### Microbiology {#Sec9}

A positive culture from ocular fluid or other body fluids was obtained in 82 patients (68.9%). The culture result of 1 patient was not available as he had it done elsewhere.

The blood was the highest source among all culture-positive results (50, 42.0%). Gram-negative organisms were more common (26 patients, 52.0%) than gram-positive organisms (20 patients, 40.0%). Four patients (8.0%) had a positive fungal culture from the blood (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Blood, other body fluids, and vitreous culture organism

Forty-six patients (38.7%) had at least one positive culture from other body fluids. Other body fluid cultures yielded gram-positive organisms in 11 patients (23.9%), gram-negative in 28 patients (23.3%), and fungal in 7 patients (15.2%). Nineteen patients (41.3%) had a positive urine culture; 14 (30.4%) had positive cultures from infected catheter, skin, soft tissue, or joint; 8 (17.4%) had positive sputum cultures; 5 (10.9%) had positive culture from liver abscess; 3 (6.5%) had positive high vaginal swab; and 1 patient (2.1%) had positive cerebrospinal fluid (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 3Other body fluid culture

Vitreous samples were obtained from 125 eyes. Vitreous culture was positive in 27 eyes (22.3%). Of these, 22 eyes (81.4%) had bacterial and 5 eyes (18.5%) had fungal isolates. Among bacterial isolates, 10 (37.0%) were gram-positive and 12 (44.4%) were gram-negative (Fig. [2](#Fig2){ref-type="fig"}).

The causative organisms cultured from the blood, vitreous, and other body fluids are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Microbial isolates from blood, other body fluids, and vitreousSpeciesBlood (*n* = patient)Other body fluids (*n* = patient)Vitreous (*n* = eyes)Culture positive50 (42.0%)46 (38.7%)27 (22.3%)Culture negative69 (58.0%)73 (61.3%)94 (77.7%)Gram-positive organism20 (40.0%)11 (23.9%)10 (37.0%) *Staphylococcus aureas*13 (26.0%)7 (15.2%)5 (18.5%) MRSA3 (6.0%)2 (4.3%)2 (7.4%) *Staphylococcus* coagulase -ve2 (4.0%)0 (0.0%)2 (7.4%) *Streptococcus* sp.2 (4.0%)2 (4.3%)1 (3.7%)Gram-negative organism26 (52.0%)28 (60.9%)12 (44.4%) *Klebsiella pneumonia*17 (34.0%)19 (41.3%)8 (29.6%) *Pseudomonas aeruginosa*2 (4.0%)4 (8.7%)3 (11.1%) *Escherichia coli*1 (2.0%)3 (6.5%)0 (0.0%) *Acinebacter* sp.1 (2.0%)2 (4.3%)0 (0.0%) *Enterobacter intermedius*1 (2.0%)0 (0.0%)0 (0.0%) *Bukholderia cepacia*1 (2.0%)0 (0.0%)1 (3.7%) *Bukholderia pseudomallei*1 (2.0%)0 (0.0%)0 (0.0%) *Elizabethkingia meningosepticum*1 (2.0%)0 (0.0%)0 (0.0%) *Mycoplasma pneumonia*1 (2.0%)0 (0.0%)0 (0.0%)Fungal4 (8.0%)7 (15.2%)5 (18.5%) *Candida albicans*1 (2.0%)5 (10.9%)1 (3.7%) *Candida tropicalis*2 (4.0%)1 (2.2%)0 (0.0%) *Penicillium* sp.0 (0.0%)0 (0.0%)2 (7.4%) *Phanerochaeta chrysosporium*0 (0.0%)0 (0.0%)1 (3.7%) *Xylariaceae* sp.0 (0.0%)0 (0.0%)1 (3.7%) Fungal (species not available)1 (2.0%)1 (2.2%)0 (0.0%)

The microbiology of causative organisms is summarized in Table [3](#Tab3){ref-type="table"}.Table 3Microbiology of causative organism in endogenous endophthalmitisNumberPercentGram-positive bacteria2732.5 *Staphylococcus aureas*1720.5 MRSA33.6 *Staphylococcus* coagulase -ve44.8 *Streptococcus* sp.33.6Gram-negative bacteria4250.6 *Klebsiella pneumonia*2732.5 *Pseudomonas aeruginosa*56.0 *Escherichia coli*33.6 *Acinebacter* sp.22.4 *Enterobacter intermedius*11.2 *Bukholderia cepacia*11.2 *Bukholderia pseudomallei*11.2 *Elizabethkingia meningosepticum*11.2 *Mycoplasma pneumonia*11.2Fungal1416.9 *Candida albicans*56.0 *Candida tropicalis*33.6 *Penicillium* sp.22.4 *Phanerochaeta chrysosporium*11.2 *Xylariaceae* sp.11.2 Fungal (species not available)22.4

### Treatment {#Sec10}

All patients were treated with systemic antibiotics or antifungal agents aimed at the source of infection and presumed causative organism. One hundred nineteen cases (85.6%) were on systemic antibiotics, and more than half (55.1%) were treated with ciprofloxacin either as monotherapy or in combination with other antibiotics. There was no statistically significant correlation between systemic ciprofloxacin and final visual outcomes (*p* = 0.68). Systemic steroids were not used in any of the patients. In addition, 126 eyes (88.7%) received intravitreal antibiotics (vancomycin and ceftazidime or amikacin) or antifungal (amphotericin B) injections or both. The injections were repeated in 75 eyes (59.5%). Intravitreal injection was not given in 16 cases (11.3%), and 10 of them (62.5%) had relatively good presenting visual acuity of 6/24 or better and mild vitritis. They were treated with systemic antibiotics or antifungals with close monitoring. No intravitreal injection of steroids was given to any eye. Overall, 69 eyes (48.6%) were managed medically either with systemic or intravitreal antibiotics or antifungals or both.

Out of 143 eyes, 73 (51.4%) underwent vitrectomy. Early vitrectomy was performed within 2 weeks from diagnosis in 38 eyes (52.1%). Silicone oil was injected in 35 eyes (47.9%), gas in 3 eyes (4.1%), air in 19 eyes (26.0%), and no intraocular tamponade was used in 16 eyes (21.9%).

### Outcomes {#Sec11}

The most common presenting visual acuity was between 6/60 and counting finger (CF) (48 eyes, 34.0%), followed by hand motion (38, 27.0%) and perception of light (22 eyes, 15.6%). Only 16 eyes (11.3%) and 14 eyes (9.9%) had presented visual acuity between 6/6 to 6/18 and 6/24 to 6/36 respectively. Overall, 56% had vision of CF or better at presentation. Vision was not available in 2 patients (1.4%) who could not cooperate during a vision test. Final visual acuity was available in 138 eyes (96.5%). Three patients were transferred to their original hospitals for the continuation of treatment and follow-up. One patient defaulted follow-up, and another patient passed away due to sepsis and multiorgan failure.

After treatment, 100 eyes (73.0%) achieved final visual acuity of CF or better. Ten eyes developed panophthalmitis, and 6 eyes required evisceration. Table [4](#Tab4){ref-type="table"} summarizes the logistic regression analysis results of patient characteristics that may predict a good visual outcome (CF or better).Table 4Prognostic factors associated with good visual outcomesPrognostic factor (referent)Crude odds ratio (95% CI)*p* value^a^Adjusted odds ratio (95% CI)*p* value^b^Gender (male) Female2 (0.92, 4.37)0.079Age (0--50 years) \> 50 years0.85 (0.39, 1.86)0.679Medical illness (yes) No1.60 (0.55, 4.63)0.383DM (yes) No2.12 (0.93, 4.85)0.071Presenting VA (≥ CF) \< CF0.10 (0.04, 0.25)0.0000.09 (0.021, 0.384)0.001Fundus view (yes) No0.15 (0.06, 0.38)0.0000.337 (0.068, 1.675)0.184Source of infection (yes) No2.61 (0.93, 7.37)0.062Culture (positive) Negative1.29 (0.54, 3.07)0.566Organism (gram+) Gram−0.965 (0.275--3.386)0.956 Fungal0.185 (0.019, 1.848)0.151Intravitreal antibiotic (yes) No2.85 (0.62, 13.2)0.234Vitrectomy (yes) No1.13 (0.53--2.41)0.751Early vitrectomy (≤ 2 weeks) \> 2 weeks1.69 (0.59--4.82)0.327The clinical summary of patients were summarized in Table [5](#Tab5){ref-type="table"}^a^Univariate logistic regression^b^Only factors associated with good visual outcome in multivariate logistic regression modelTable 5Clinical summary of endogenous endophthalmitis in the current studyCaseAge/sex/eyeSystemic risk factorsInitial VACultureOrganismSource of infectionSystemic antibiotics/antifungalIVT abk/antifungalVitrectomyFinal VABloodOther body fluidsVitreous149/M/R--CF++ Sputum−*Acinetobacter* sp.Skin infectionCiprofloxacinYesYes6/18276/F/R--PL−+ Skin−*Candida albicans*Skin infectionFluconazoleYesYesNPL349/M/LDM4/60−+ Skin−*Staphylococcus aureus*Skin infectionUnasynYesNo6/36446/F/L--NAV−+ Sputum−*Acinetobacter* sp.Lung infectionCeftriaxone, sulperazoneYesNoNAV539/F/LLeukemia6/36−−−----Amphotericin, fluconazoleYesyes6/9671/M/L--CF+−−*Klebsiella pneumonia*UTICefuroximeYesNo6/24756/F/RDMNPL−−−--Lung infectionCiprofloxacinYesNoNPL856/M/LLeukemia6/60+−−*Enterobacter intermedius*--Vancomycin, moxifloxacinYesNoHM926/M/R--6/36+−Not done*Staphylococcus aureus*IECloxacillin, gentamicinNoNo6/361026/M/L--6/9+−Not done*Staphylococcus aureus*IECloxacillin, gentamicinNoNo6/61161/M/RDMCF++ Urine−*Candida albicans*UTIFluconazole, voriconazoleYesYes6/91261/M/LDM6/36++ Urine−*Candida albicans*UTIFluconazole, voriconazoleYesYes6/91360/M/RDMPL−+ Liver, + sputum−*Klebsiella pneumonia*HPB infectionCiprofloxacin, cefuroxime, metronidazoleYesYesPL1460/M/LDMPL−+ Liver, + sputum−*Klebsiella pneumonia*HPB infectionCiprofloxacin, cefuroxime, metronidazoleYesNoNPL1549/M/RDMHM−+ Urine−*Staphylococcus aureus*DFUCiprofloxacinYesYesCF1649/M/LDMHM−+ Urine−*Staphylococcus aureus*DFUCiprofloxacinYesYesNPL1752/F/LDMCF−−−----Ciprofloxacin, vancomycinYesNoCF1857/M/LDM, renal failureCF−+ Infected catheter+*Pseudomonas aeruginosa*DFUCiprofloxacin, ceftazidime, meropenemYesYesNPL1938/F/LDMHM−−−--HPB infectionCiprofloxacinYesYesHM2071/F/RDMCF+−−*Staphylococcus* coagulase -veLung infectionCefuroximeYesNo6/602149/F/LRenal failure on steroidCF−−−----FluconazoleYesYes6/122268/M/LDM, malignancy6/12−+ SputumNot done*Pseudomonas aeruginosa*Lung infectionCeftriaxone, cefuroximeNoNo6/92356/M/LDM, renal failure, hydronephrosis4/60+−−*Staphylococcus aureus*Infected catheterCloxacillinYesNo4/602430/F/RDMPL−+ Urine+*Klebsiella pneumonia*UTIVancomycin, ceftazidimeYesYesPL2565/F/R--6/60−−−--UTINAVYesYes6/242619/F/RSLE with lupus nephritis, on steroid6/6+−−*Staphylococcus aureus*Infected catheterVancomycinYesNo6/182775/F/RDM6/18−+ SputumNot done*Klebsiella pneumonia*Lung infectionCiprofloxacinNoNo6/242875/F/LDMCF−+ Sputum−*Klebsiella pneumonia*Lung infectionCiprofloxacinYesYesPL2951/F/RDMHM−+ HVS−*Candida albicans*--FluconazoleYesYes6/93053/F/L--HM+−−*Staphylococcus aureus*--CiprofloxacinYesYesCF3149/M/LDMHMNAVNAV−NAVHPB infectionNAVYesYesCF3219/M/R--HM−−Not done--MeningitisCiprofloxacinYesNoNAV3365/F/LCNS lymphomaCF−−−----CiprofloxacinYesYesCF3477/M/R--CF−−−----Ciprofloxacin, fluconazoleYesYes6/363527/F/R--6/24−−Not done--Lung infectionNAVNoNo6/93627/F/L--6/24−−Not done--Lung infectionNAVNoNo6/93756/F/R--3/60+−Not done*Staphylococcus aureus*UTIC-penicillin, unasynNoNo6/93862/M/RDM6/12++ UrineNot done*Streptococcus* sp.UTIPiperacillin-tazobactamYesNo6/93962/M/LDMPL++ Urine−*Streptococcus* sp.UTIPiperacillin-tazobactamYesNo6/184034/M/RRenal failureHM−+ UrineNAV*Klebsiella pneumonia*UTISulperazoneYesNo3/604163/M/LDMCF−+ SputumNot done*Klebsiella pneumonia*Lung infectionTrimethoprime, sulphamethoxazoleNoNoCF4230/F/R--6/60−−−--Skin infectionCloxacillinYesNo6/64330/F/L--6/24−−Not done--Skin infectionCloxacillinYesNo6/64461/F/RDM, sigmoid colon carcinomaCF−−−--Infected catheterCiprofloxacin, fluconazoleYesYes6/364540/M/L--HM−−−--HPB infectionCiprofloxacin, meropenemYesYesNPL4653/M/RDMHM−−−--Lung infectionCefoperazoneYesNo6/604753/M/LDMHM−−−--Lung infectionCeftriaxoneYesNoHM4857/M/RDMHM−−+*Staphylococcus aureus*UTIVancomycinYesYesHM4957/M/LDM3/60−−+*Staphylococcus aureus*UTIVancomycinYesYesNPL5070/M/RDM, hydronephrosisHM+−−*Staphylococcus aureus*Infected catheterCloxacillin, gentamicinYesNo6/185170/M/LDM, hydronephrosisHM+−−*Staphylococcus aureus*Infected catheterCloxacillin, gentamicinYesNoCF5219/M/LTakayashu arteritis, renal failure on steroid2/60−−−----Ciprofoxacin, ceftazidimeYesNo6/185356/F/RDM6/18++ Liver−*Klebsiella pneumonia*HPB infectionCefuroximeYesNo6/185456/M/RDMHM+−−MRSAInfected catheterCiprofloxacinYesNoCF5556/M/LDMCF+−−*Klebsiella pneumonia*Lung infectionCeftazidimeYesNoNPL5657/M/R--CF−−−----CiprofloxacinYesNo6/125757/M/L--6/12−−Not done----CiprofloxacinYesNo6/125838/F/L--6/9−+ Urine−*Escherichia coli*UTICeftazidimeNoNo6/95955/M/RDMCF−+ Infected catheter−*Staphylococcus aureus*Skin infectionCeftriaxoneYesNoCF607/M/RLeukemia6/36−+ Infected catheter−Fungal\*Septic arthritisItraconazoleYesYes6/96142/F/R--CF+−−*Bukholderia pseudomallei*--CiprofloxacinYesNo6/246263/F/RDMNAV++ Urine/infected catheterNot done*Klebsiella pneumonia*Skin infectionCiprofloxacinNoNoNPL6371/F/L--HM−−NAV--Lung infectionCiprofloxacinNAVNAVNAV6422/F/LLeukemia6/24+−Not doneFungal\*--VoriconazoleNoNo6/186545/M/LDM, renal failureNPL++ Infected catheter−*Staphylococcus aureus*Infected catheterCloxacillinYesNoNPL6648/M/RDMCF+−−*Klebsiella pneumonia*Lung infectionCeftriaxone, amoxicillin-clavulanic acidYesYes6/606731/M/L--CF−−−----CiprofloxacinYesYes6/66854/M/L--6/60++ Sputum, CSF+*Klebsiella pneumonia*Lung infectionCeftriaxone, imipenemYesNoNPL6955/M/RDM, renal failureHM++ Infected catheter−*Staphylococcus aureus*Skin infectionCiprofloxacinYesYes6/607055/M/LDM, renal failureHM++ Infected catheter−*Staphylococcus aureus*Skin infectionCiprofloxacinYesYes6/367114/F/L--6/36−−Not done----Ceftazidime, trimethoprime, sulphamethoxazoleNoNo6/187242/F/L--6/60−−−--HPB infectionCiprofloxacin, CeftazidimeYesYesCF7330/F/R--6/12−+ HVS−*Steroptococcus* sp.Genital infectionc-penicillinYesNo6/127467/F/LDMHM−−−--Lung infectionCeftazidimeYesNoNAV7565/M/L--CF−+ Liver−*Klebsiella pneumonia*HPB infectionCiprofloxacin, imipenemYesYesCF7634/F/RLeukemiaPL+−−*Candida tropicalis*--VoriconazoleYesNoNPL7734/F/LLeukemiaCF+−−*Candida tropicalis*--VoriconazoleYesYes6/607858/M/RDM, renal failureNPL++ Urine+*Pseudomonas aeruginosa*UTICiprofloxacin, metronidazoleNoNoNPL7955/F/RDM6/60+−+*Bukholderia cepacia*MeningitisCeftazidimeYesNo6/368025/M/L--PL+−+*Steroptococcus* sp.--CloxacillinYesYesNPL8148/F/L--6/60−−−----CeftazidimeYesNo6/188252/F/LDMCF++ Urine−*Pseudomonas aeruginosa*UTICiprofloxacinYesYesCF8355/F/LDMHM+−−*Klebsiella pneumonia*Lung infectionAmoxicillin-clavulanic acid, azithromycinYesYesCF8474/M/LDM, renal carcinomaCF−−−--Skin infectionCiprofloxacin, fluconazoleYesYes6/248537/F/RDMHM+−−--Lung infectionCiprofloxacinYesYes5/608666/F/RDMPL−+ Infected catheter+*Klebsiella pneumonia*Skin infectionCiprofloxacinYesYesCF8766/F/LDMPL−+ Infected catheter+*Klebsiella pneumonia*Skin infectionCiprofloxacinYesNoCF8850/F/RDMHM+−−*Staphylococcus* coagulase -veUTICiprofloxacinYesNo6/98965/M/RDM, alcoholic liver diseaseCF−+ Urine−*Candida albicans*HPB infectionFluconazoleYesYesCF9065/M/LDM, alcoholic liver diseaseCF−+ Urine−*Candida albicans*HPB infectionFluconazoleYesYes3/609149/F/LDM6/9−−−--Skin infectionCiprofloxacin, fluconazoleYesYesHM9241/F/RLeukemia6/7.5+−Not done*Candida tropicalis*--VoriconazoleYesNo6/99341/F/LLeukemia6/60+−−*Candida tropicalis*--VoriconazoleYesNo6/189458/M/RDM, liver disease6/36−−−----CeftazidimeYesNo6/99555/F/RAuto-immune hepatitis on steroid and immunosuppressantCF−−−----CiprofloxacinYesNo6/129681/M/R--HM−−−----CiprofloxacinYesYes6/129732/F/RLeukemia6/24−−+*Xylariaceae* sp.--VoriconazoleYesYesCF9832/F/LLeukemia6/12−−−----VoriconazoleYesYes6/129963/F/R--HM−−+*Staphylococcus* coagulase -veSkin infectionCiprofloxacinYesYes6/910054/M/LDM, renal failurePL++ Infected catheter+*Staphylococcus aureus*Infected catheterCiprofloxacin, amoxicillin-clavulanic acidYesNoNPL10146/F/RDMHM−−+*Penicillium* sp.--Amphotericin, fluconazoleYesYesCF10264/M/LDM, rectal carcinomaPL−−−----CiprofloxacinYesYesHM10366/M/LDM6/24+−+*Mycoplasma pneumonia*Lung infectionCiprofloxacin, azithromycinYesYes6/910459/F/LDM, renal failureHM−−−----CiprofloxacinYesYesCF10570/M/RDMPL−−+*Penicillium* sp.--ItraconazoleYesYes6/3610641/F/RDMHM−−−--Lung infectionCiprofloxacinYesYesPL10767/M/LDM6/9++ Urine+Escherichia coliUTICiprofloxacinYesYesCF10863/M/R--1/60++ Infected catheter+MRSASkin infectionVancomycin, ciprofloxacinYesYes6/910963/M/L--6/24++ Infected catheterNot doneMRSASkin infectionVancomycin, ciprofloxacinNoNo6/1211052/M/LDM, renal failureHM−−+*Phanerochaete chrysosporium*Skin infectionVoriconazoleYesNoCF11145/M/RDM, renal failurePL+−−*Staphylococcus aureus*Infected catheterCloxacillinYesYesNPL11247/M/RAlcoholic liver disease on steroid6/12+−Not done*Staphylococcus aureus*Skin infectionCloxacillinNoNo6/911347/M/LAlcoholic liver disease on steroid6/12+−Not done*Staphylococcus aureus*Skin infectionCloxacillinNoNo6/911458/M/LDMPL++ Infected catheter+MRSAGenital infectionCiprofloxacinYesYesHM11567/F/R--6/36−+ Urine+*Klebsiella pneumonia*UTICefuroximeYesYesCF11648/M/LDMHM−−Not done--Skin infectionCiprofloxacinYesYes6/1811778/F/L--CF−−+*Staphylococcus* coagulase -ve--Ciprofloxacin, ceftazidimeYesYes3/6011861/F/LDMPL−+ Urine−*Klebsiella pneumonia*UTICiprofloxacin, meropenemYesYesCF11955/F/LDM3/60++ Sputum−*Klebsiella pneumonia*Lung infectionCeftazidimeYesYes6/1212055/M/L--PL+−+*Klebsiella pneumonia*HPB infectionCeftriaxone, ciprofloxacin, metronidazoleYesNoNPL12160/M/RDMPL++ Infected catheter+*Staphylococcus aureus*Skin infectionCloxacillin, ceftazidimeYesNoHM12260/M/LDMPL++ Infected catheter+*Staphylococcus aureus*Skin infectionCloxacillin, ceftazidimeYesYesHM12340/F/RDM/liver cirrhosis, myelodysplastic syndrome6/18++ Infected catheter−*Klebsiella pneumonia*Lung infectionCefuroxime, piperacillin-tazobactamYesYesCF12432/F/LDM6/60+−−*Klebsiella pneumonia*UTICefuroximeYesNo6/1212534/F/LDMHM−+ Urine+*Candida albicans*--AmphoterinYesYes6/1812657/F/RDMPL+−−*Klebsiella pneumonia*AGECiprofloxacinYesYesNAV12748/M/RDMPL−−−--DFUCiprofloxacin, CeftazidimeYesNoNPL12865/F/RDM1/60−+ Urine−*Klebsiella pneumonia*UTICiprofloxacinYesNo6/6012965/F/RDM, renal failureHM−−−----CiprofloxacinYesYesCF13072/F/LDMHM−+ Urine−*Escherichia coli*UTICiprofloxacin, trimethoprime, sulphamethoxazoleYesNoNPL13155/F/RDMHM+−−*Klebsiella pneumonia*HPB infectionCeftriaxoneYesYesHM13267/M/RAdenocarcinoma of lung and colonHM−−−--Infected catheterFluconazole, voriconazoleYesYesNPL13368/F/LDM, renal failureCF+−−*Elizabethkingia meningocepticum*Infected catheterCeftazidime, cefazolin, vancomycinYesNoCF13468/F/RDM, renal failure6/24+−−*Elizabethkingia meningocepticum*Infected catheterCeftazidime, cefazolin, vancomycinYesNo6/1213561/F/LDM, renal failureHM+−−*Staphylococcus aureus*Infected catheterCloxacillinYesNo6/3613644/M/LDMPL++ Liver+*Klebsiella pneumonia*HPB infectionCeftazidime, imipenemYesNoNPL13765/M/LDM, chronic cystitisCF−+ Urine−*Klebsiella pneumonia*UTICiprofloxacinYesYesCF13859/F/LDM, renal FailureHM−−−--Skin infectionCiprofloxacinYesYes6/1813967/F/LHepatolithiasisPL++ Liver−*Klebsiella pneumonia*HPB infectionCiprofloxacin, imipenemYesNoNPL14076/M/RDMCF−+ Urine−*Candida albicans*UTIFluconazoleYesYes6/914176/M/LDMCF−+ Urine−*Candida albicans*UTIFluconazoleYesYes6/2414238/F/R--HM−−+*Pseudomonas aeruginosa*--Ceftriaxone, ciprofloxacin, metronidazoleYesYesHM14369/M/LDMHM++ Urine+*Klebsiella pneumonia*UTICefepime, amoxicillin-clavulanic acidYesYes1/60*Abbreviation*: *IVT* intravitreal, *abk* antibiotic, *DM* diabetes mellitus, *NAV* not available, *UTI* urinary tract infection, *IE* infective endocarditis, *HPB* hepatobiliary, *DFU* diabetic foot ulcer, *AGE* acute gastroenteritis, *MRSA* methicillin-resistant *Staphylococcus aureus*, *CF* counting finger, *HM* hand movement, *PL* perception of light, *NPL* non-perception of light

In univariate logistic regression analysis, factors found to be statistically significant with good visual outcome were good presenting visual acuity (crude odd ratio 0.1; 95% CI 0.021, 0.384) and presence of fundus view at presentation (crude odd ratio 0.337; 95% CI 0.068,1.675). In the multivariate logistic regression analysis, elevated risk for good visual outcome was observed only in good presenting visual acuity (adjusted odd ratio 0.09; 95% CI 0.021, 0.384). We also found a moderate correlation between presenting visual acuity and final visual acuity (Pearson *r* = 0.564, *p* \< 0.001 (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Correlation between presenting visual acuity (LogMAR) and final visual acuity (LogMAR)

Gender, age group, presence of underlying medical illness, existing DM, source of infection, culture positivity, types of organism, intravitreal antibiotics, vitrectomy, or early vitrectomy were not significantly associated with good final visual outcomes.

Discussion {#Sec12}
==========

In this study, we wanted to determine whether the clinical profiles of EE at a tertiary hospital in Malaysia were similar to those reported from other countries.

Previous studies had reported a male preponderance with unilateral involvement \[[@CR7]--[@CR10]\]. In contrast, our results showed no difference between male and females.

Predisposing conditions are important in determining a patient's risk for endogenous endophthalmitis. Okada et al. reported 90% of patients had a positive history of underlying medical conditions such as diabetes, cardiac disease, and malignancy \[[@CR2]\]. A major review of endogenous endophthalmitis demonstrated underlying medical conditions predisposing to ocular infection in 56 to 68% of cases \[[@CR4]\]. Another study conducted by Wu and colleagues revealed the identification of preexisting predisposing condition in 90.9% of patients, and the most common systemic condition found was diabetes mellitus (50%) \[[@CR11]\]. In contrast, Connell et al. reported that intravenous drug abuse was the most common risk factor \[1\]. Several East Asian studies reported that diabetes mellitus was the most common, and hepatobiliary disease was the second most frequent underlying disease \[[@CR5], [@CR12]--[@CR14]\]. In a review of 57 cases of endogenous endophthalmitis in Korea, diabetes mellitus (46.5%) was the most common underlying disease followed by liver cirrhosis (20.9%) \[[@CR15]\]. In a recent study in which all patients had one or more preexisting medical conditions, the most common was also diabetes mellitus (61.9%) \[[@CR16]\]. Our series revealed similar results, in which diabetes mellitus was the most common systemic disease (60.0%) followed by renal failure and malignancy. However, liver diseases were identified only in 6 patients.

In a review of cases by Wong et al., it was reported that hepatobiliary tract infection was the most common source of bacteremia (13 patients, 48%) \[[@CR5]\]. Similar results were found in other Korean case series \[[@CR12], [@CR15], [@CR17]\]. Interestingly, our case series did not show similar findings with other East Asian reports. We found that urinary tract infection (21, 17.5%) was the most common source of bacteremia followed by pulmonary infection (19, 15.8%). Hepatobiliary tract infection was only identified in 12 patients (10.0%). We also found that among patients who were younger than 40 years old, and older than 60 years old, the most common systemic infection was urinary tract infection at 17.4% and 30.0% respectively. In contrast, lung infection (17.5%) followed by hepatobiliary infection (14.0%) was the commonest infections among those aged from 40 to 60 years old.

In a case series by Lim et al., the most common presenting complaint was decreased vision (68.8%) followed by ocular discomfort (44%), red eye (20.8%), and ocular pain (17.4%) \[[@CR15]\]. Ratra et al. also reported that reduced vision (60, 98.4%), redness (47, 77%), and pain (42, 68.8%) were the three most common presenting symptoms \[[@CR8]\]. Similar to these studies, our study too revealed blurring of vision, eye redness, and eye pain or discomfort as the main presenting ocular symptoms. However in a case series by Nishida et al., floaters was the second most common ocular symptom after blurring of vision \[[@CR16]\].

Ratra et al. in their case series demonstrated that all eyes had severe diffuse endophthalmitis involving the posterior pole. Diffuse vitreous exudates were seen in 47 eyes (77%). Retina could be visualized in 13 eyes (21.3%), and 3 (4.9%) had retinal detachment. None had panophthalmitis \[[@CR8]\]. In another case series in 18-year review of culture-positive cases in 34 affected eyes, the most common findings were decreased visual acuity (91.1%), vitritis (79.4%), conjunctival injection (67.6%), iritis or retinitis (61.7%), hypopyon (35.2%), and retinal detachment (5.8%) \[[@CR18]\]. In our study, 27 eyes (19%) had hypopyon, 64 eyes (44.8%) had fundus view, and 8 eyes (8.2%) were noted to have retinal detachment on ultrasound. Lower percentage of hypopyon in our patients could be due to the application of topical steroids and antibiotics by the referring ophthalmologist.

The diagnosis of endogenous endophthamitis is typically made following microbiologic evidence of infection from intraocular samples (aqueous or vitreous). Positive cultures from the blood, cerebrospinal fluid, or any extraocular site can be highly suggestive. In our series, the organism causing endophthalmitis was identified by a positive culture from at least one body fluid source in 82 patients (68.9%). Blood culture positivity rate varies widely, from 33 to 94% \[[@CR4], [@CR19]\]. Previous large case series have shown higher rates of positivity following blood cultures as compared to vitreous aspirates possibly due to a larger volume sampled \[[@CR2], [@CR4], [@CR11]\]. In contrast, Ratra et al. had reported that ocular fluid samples tended to give positive culture results more than blood (58.6% vs 3.4%). This is because all the patients with suspected endogenous endophthalmitis immediately underwent an aqueous tap in the outpatient department before any intravitreal therapy \[[@CR8]\]. High rate of positive cultures from intraocular specimens was also demonstrated by Okada et al. (86%), Binder et al. (70%), and Ness et al. (81%) \[[@CR2], [@CR20], [@CR21]\]. Vitrectomy has a higher diagnostic yield for culture (92%) compared to a vitreous aspirate (44%) \[[@CR22]\]. Vitreous samples during vitrectomy were taken near the retinal surface, which can potentially explain the lower yield of needle biopsy. This is because early or localized infection located near the retinal surface might be missed by a needle biopsy \[[@CR23]\]. We noted low vitreous yield of organisms in our study. This could be because some of our patients with systemic infection were initially managed by physicians depending on the source of infection. During the time of referral, most of them were already on systemic antibiotics or partially treated. Furthermore, the diagnosis may have been delayed in some while others were generally not stable for early vitreous tapping. Thirty-six patients (30.0%) in our series were culture negative.

Causative organisms vary geographically. Studies from the western population revealed that fungal infection was the main source in predisposed states, such as intravenous drug abusers and immunocompromised patients \[[@CR1], [@CR19], [@CR21]\]. In contrast, gram-negative microbes as the causative organisms were overwhelming in the East Asian experience. In these Asian populations, *Klebsiella* was found to be responsible for approximately 90% of all endogenous bacteria endophthalmitis cases \[[@CR5]\]. Studies that were conducted in Korea showed that liver abscess was the most common infection source and *Klebsiella* was the most common causative agent \[[@CR15], [@CR17]\]. A study from Japan in 2015, however, demonstrated that gram-positive organisms were more common (76.2%) than gram-negative (19.0%), contrasted to the findings from other East Asian studies \[[@CR16]\]. *K*. *pneumonia* which is predominant in East Asia may be due to the high incidence of cholangiohepatitis. Therefore, the East Asian population is more prone to have liver abscess than Caucasians \[[@CR24]\]. We found that gram-negative organisms were responsible for half of the cases of endogenous endophthalmitis in our case series (42 patients, 50.6%) in which *K*. *pneumonia* was the most common organism isolated (27 patients, 32.5%). Interestingly, in contrast to several East Asian studies, urinary tract infection including renal abscess (9 patients, 33.3%) was the most common source of infection caused by *K*. *pneumonia* followed by lung infection (8 patients, 29.6%) in our series. Liver abscess was identified in 7 patients (25.9%). Necrotizing fasciitis, infected wound breakdown, and acute gastroenteritis (AGE) were noted in one patient each. Apart from that, there was a relatively higher frequency of gram-positive cocci and fungal infection in our study, 32.5% and 16.9% respectively.

Most systemically administered antimicrobials that have been used in the therapy of endophthalmitis do not penetrate well into the non-inflamed vitreous humor. However, the penetration of several antibiotics into the eye may be increased by inflammation which occurs following surgery, trauma, or infection. Kowalski and colleagues compared the minimum inhibitory concentration (MIC) of bacterial isolates from 66 patients with endophthalmitis and found that all of the gram-negative isolates would have been inhibited by levels of ciprofloxacin achievable following systemic administration \[[@CR25]\].

In endogenous endophthalmitis, the rationale for use of intravitreal injections as an adjunct to intravenous therapy is also because of reduced permeability of the retinal-pigmented epithelium to systemically administered drugs \[[@CR26]\]. Yonekawa et al. showed that early administration, e.g., within 24 h, was associated with a favorable visual outcome \[[@CR27]\]. Most of our patients received intravitreal injections within 24 h of diagnosis.

Vitrectomy serves as a diagnostic and therapeutic option. It is indicated in cases with severe vitreous opacities, diffuse retinal infiltration, and poor presenting visual acuity and when there is no clinical improvement with systemic and intravitreal therapy. However, the role and timing of vitrectomy remain unclear in patients with endogenous endophthalmitis. Sheu et al. reported no significant relationship between vitrectomy and visual outcome in *Klebsiella* endophthalmitis. However, they suggested early vitrectomy should be considered in patients whose anterior chamber inflammation did not respond well to intravitreal antibiotics \[[@CR28]\]. On the other hand, Yoon et al. demonstrated that following early vitrectomy for *Klebsiella* endogenous endophthalmitis, 50% achieved a vision of CF or better after 6 months \[[@CR14]\]. Early vitrectomy performed within 10 days of the appearance of ocular symptoms or signs resulted in a better visual prognosis (CF or better) than without vitrectomy \[[@CR17]\]. In other studies, early vitrectomy within 2 weeks of presentation in severe cases or suspected virulent organisms was associated with good overall outcome \[[@CR14], [@CR17]\]. In our case series, 73 eyes (51.4%) underwent vitrectomy. Vitrectomy was performed within 2 weeks in 38 eyes (52.1%) and more than 2 weeks in 35 eyes (47.9%). The most common indication for early vitrectomy was poor presenting visual acuity of CF or worse in 31 cases (81.6%). Persistent or increased vitreous opacities or anterior chamber cells despite systemic and intravitreal antibiotics were other indications for early vitrectomy. There was no significant difference between early vitrectomy (within 2 weeks) compared to delayed vitrectomy (more than 2 weeks) for favorable visual prognosis (*p* = 0.327).

Generally, the visual outcome of endogenous endophthalmitis is poor due to early and extensive retinal involvement. Virulent causative organisms, poor host defense, misdiagnosis leading to delayed treatment, inadequate treatment, inappropriate therapy, and occurrence of complications such as panophthalmitis are associated with poor prognosis. Wu et al. reported that the eyes with bacterial endogenous endophthalmitis had a worse outcome compared to patients with fungal endophthalmitis \[[@CR11]\]. Lim et al. concluded that gram-negative bacteria had worse visual outcomes compared to gram-positive bacteria or fungus \[[@CR15]\].

Visual outcomes in *Klebsiella* endophthalmitis has been poor despite treatment with a combination of systemic and intravitreal antibiotics \[[@CR12], [@CR13]\]. Case series and literature reviews involving infection with *K*. *pneumonia* showed that visual acuity achieved was CF or better in 34.0% of eyes, and 16.0% had evisceration or enucleation \[[@CR5]\]. Sheu et al. reported 19 eyes (35.8%) had final visual acuity of CF or better \[[@CR28]\]. Connell et al. found that all the patients in their study needing enucleation were infected by *Klebsiella* \[[@CR1]\]. In our series, 100 eyes (73.0%) achieved final visual acuity of CF or better. However, in cases with *Klebsiella* endogenous endophthalmitis, only 18 eyes (25.4%) achieved final visual acuity of CF or better, which is comparable with other studies. Ten eyes were complicated with panophthalmitis, and 5 of them were due to *Klebsiella pneumonia*.

In our series, a good presenting visual acuity was the only prognostic factor associated with good visual outcomes of CF or better. Lim et al., Nishida et al., and Binder et al. in their case series also described that a good presenting visual acuity was significantly associated with good final visual acuity \[[@CR15], [@CR16], [@CR20]\]. We found that DM, presence of a source of infection, organism, and intravitreal antibiotics were not related to poor visual outcome.

Study limitation {#Sec13}
----------------

This study is limited by the retrospective design. As the data was collected retrospectively, some of the information was not available. Apart from that, patients with culture-negative result were also included in this study which may have included those with non-infectious uveitis. In the future, we may need to use other methods such as polymerase chain reaction (PCR) with higher sensitivity and specificity. Lack of uniform guidelines and treatment protocol is another limitation. Observational and prospective case series are needed in the future to assess long-term outcomes.

Conclusions {#Sec14}
===========

The visual prognosis of endogenous endophthalmitis (EE) is poor. Gram-negative organisms specifically *Klebsiella pneumonia* were the most common organisms isolated. Urinary tract infection was the main source of infection. Poor presenting visual acuity was significantly associated with poor visual outcomes.

AGE

:   Acute gastroenteritis

CF

:   Counting fingers

EE

:   Endogenous Endophthalmitis

MRSA

:   Methicillin-resistant *Staphylococcus aureus*

PCR

:   Polymerase chain reaction
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